MiMedx Group Inc MDXG

Morningstar Rating
$4.67 +0.05 (1.08%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MDXG is trading at a LOCK|^Vf$#< premium.
Price
$4.68
Fair Value
LOCK|qrHlz<&
Uncertainty
LOCK|FFy
1-Star Price
LOCK|.Lmy<#^>
5-Star Price
LOCK|!t>nW>
Economic Moat
LOCK|Qm
Capital Allocation
—

News

Trading Information

Previous Close Price
$4.62
Day Range
$4.58–4.70
52-Week Range
$3.03–7.97
Bid/Ask
$4.50 / $4.78
Shares Outstanding
145.93M
Market Cap
$681.51M
Volume/Avg
391,115 / 1M

Key Statistics

Price/Earnings (Normalized)
25.37
Price/Sales
1.96
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
2.15%

Company Profile

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
808

Valuation

Metric
MDXG
Price/Earnings (Normalized)
25.37
Price/Book Value
3.15
Price/Sales
1.96
Price/Cash Flow
18.01
Price/Earnings
MDXG

Financial Strength

Metric
MDXG
Quick Ratio
4.60
Current Ratio
5.33
Interest Coverage
—
Quick Ratio
MDXG

Profitability

Metric
MDXG
Return on Assets (Normalized)
9.36%
Return on Equity (Normalized)
12.32%
Return on Invested Capital (Normalized)
10.40%
Return on Assets
MDXG

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|q!r%s<LOCK|%n?<$129B
Moderna Inc
MRNA
LOCK|@md<KqLOCK|v!$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|z$$>@VLOCK|#Sw%$77B
argenx SE ADR
ARGX
LOCK|&hPz?&?LOCK|@^t$51B
BeOne Medicines Ltd ADR
ONC
LOCK|!Qk>?&LOCK|@hm$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|#Ns>@b?LOCK|g@Bl$31B
Royalty Pharma PLC Class A
RPRX
LOCK|Rk^@X?#LOCK|xnlJ?$25B
BioNTech SE ADR
BNTX
LOCK|!<n%d^HLOCK|<^J$24B
Incyte Corp
INCY
LOCK|yj?V<!LOCK|QX$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|ncb?>P#LOCK|>T$14B

Sponsor Center